Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SPRO Spero Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: SPRO
Price (delayed)
$2.66
Market cap
$148.72M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.28
Enterprise value
$103.8M
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Highlights
The debt has declined by 24% year-on-year and by 8% since the previous quarter
SPRO's quick ratio is down by 34% year-on-year but it is up by 17% since the previous quarter
The equity has dropped by 65% year-on-year and by 27% since the previous quarter
SPRO's revenue has plunged by 60% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of SPRO
Market
Valuations
Earnings
Shares outstanding
55.91M
Market cap
$148.72M
Enterprise value
$103.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.4
Price to sales (P/S)
3.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.33
Revenue
$44.58M
Gross profit
$44.58M
Operating income
-$74.11M
Net income
-$69.76M
EBIT
-$69.76M
EBITDA
-$69.76M
Free cash flow
-$33.38M
Per share
Balance sheet
Liquidity
EPS
-$1.28
EPS diluted
-$1.28
Free cash flow per share
-$0.6
Book value per share
$0.6
Revenue per share
$0.81
TBVPS
$1.4
Total assets
$77.71M
Total liabilities
$43.9M
Debt
$3.96M
Equity
$33.81M
Working capital
$45.56M
Debt to equity
0.12
Current ratio
2.56
Quick ratio
2.51
Net debt/EBITDA
0.64
Margins
Efficiency
Dividend
EBITDA margin
-156.5%
Gross margin
100%
Net margin
-156.5%
Operating margin
-166.2%
Return on assets
-59%
Return on equity
-123.5%
Return on invested capital
-364.5%
Return on capital employed
-143.7%
Return on sales
-156.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SPRO stock price
How has the Spero Therapeutics stock price performed over time
Intraday
0.76%
1 week
13.19%
1 month
311.13%
1 year
86.01%
YTD
158.25%
QTD
269.44%
Financial performance
How have Spero Therapeutics's revenue and profit performed over time
Revenue
$44.58M
Gross profit
$44.58M
Operating income
-$74.11M
Net income
-$69.76M
Gross margin
100%
Net margin
-156.5%
SPRO's revenue has plunged by 60% YoY and by 7% from the previous quarter
The gross profit has plunged by 60% YoY and by 7% from the previous quarter
The net margin has declined by 10% since the previous quarter
SPRO's operating margin is down by 9% since the previous quarter
Price vs fundamentals
How does SPRO's price correlate with its fundamentals
Growth
What is Spero Therapeutics's growth rate over time
Valuation
What is Spero Therapeutics stock price valuation
P/E
N/A
P/B
4.4
P/S
3.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.33
The price to book (P/B) is 83% more than the 5-year quarterly average of 2.4
The equity has dropped by 65% year-on-year and by 27% since the previous quarter
SPRO's P/S is 73% below its 5-year quarterly average of 12.4
SPRO's revenue has plunged by 60% YoY and by 7% from the previous quarter
Efficiency
How efficient is Spero Therapeutics business performance
SPRO's ROIC has shrunk by 62% QoQ
Spero Therapeutics's ROE has decreased by 30% from the previous quarter
The return on assets has declined by 21% since the previous quarter
The return on sales has declined by 10% since the previous quarter
Dividends
What is SPRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SPRO.
Financial health
How did Spero Therapeutics financials performed over time
SPRO's total assets is 77% higher than its total liabilities
SPRO's total assets has shrunk by 54% YoY and by 30% QoQ
SPRO's total liabilities is down by 39% year-on-year and by 32% since the previous quarter
The debt is 88% smaller than the equity
The debt to equity has soared by 140% YoY and by 33% from the previous quarter
The equity has dropped by 65% year-on-year and by 27% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.